trending Market Intelligence /marketintelligence/en/news-insights/trending/LnLM6YPmNsPWQVweDI7CvA2 content esgSubNav
In This List

Indivior application for schizophrenia treatment accepted by US FDA

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Indivior application for schizophrenia treatment accepted by US FDA

The U.S. Food and Drug Administration accepted Indivior PLC's application for RBP-7000, an investigational treatment for schizophrenia.

Schizophrenia is a chronic disorder characterized by a lifelong pattern of acute psychotic episodes superimposed upon chronically poor psychosocial adjustment.

The FDA is expected to approve the drug by July 28, 2018.